200124-22-7 Usage
Description
BOC-ARG(PBF)-OH, also known as Nalpha-Boc-Nμ-(2,2,4,6,7-pentamethyl-2,3-dihydrobenzo[b]furan-5-sulfonyl)-L-arginine, is a chemical compound that serves as a protected form of L-arginine. It is characterized by its potential applications in various fields, including peptide synthesis and pharmaceutical research. The compound may contain approximately 10% solvent.
Uses
1. Used in Peptide Synthesis:
BOC-ARG(PBF)-OH is used as a protected form of L-arginine for the synthetic preparation of peptides. It plays a crucial role in the production of autophagosomal marker lipoprotein LC3-II, which is essential for understanding the process of autophagy in cells.
2. Used in Anticancer Research:
BOC-ARG(PBF)-OH has been utilized as a building block in the synthesis of anticancer amphipathic peptide-dendronized compounds. These compounds exhibit potential applications in the development of novel anticancer drugs, targeting various types of cancer cells.
3. Used as a Triflating Reagent:
In addition to its applications in peptide synthesis and anticancer research, BOC-ARG(PBF)-OH is also used as a triflating reagent. This application highlights its versatility in chemical reactions and its potential use in various industries, including pharmaceuticals and materials science.
Check Digit Verification of cas no
The CAS Registry Mumber 200124-22-7 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,0,0,1,2 and 4 respectively; the second part has 2 digits, 2 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 200124-22:
(8*2)+(7*0)+(6*0)+(5*1)+(4*2)+(3*4)+(2*2)+(1*2)=47
47 % 10 = 7
So 200124-22-7 is a valid CAS Registry Number.
InChI:InChI=1/C24H38N4O7S/c1-13-14(2)19(15(3)16-12-24(7,8)34-18(13)16)36(32,33)28-21(25)26-11-9-10-17(20(29)30)27-22(31)35-23(4,5)6/h17H,9-12H2,1-8H3,(H,27,31)(H,29,30)(H3,25,26,28)/t17-/m0/s1
200124-22-7Relevant articles and documents
REPROGRAMMING UROKINASE INTO AN ANTIBODY-RECRUITING ANTICANCER AGENT
-
Page/Page column 13; 80; 81, (2013/05/23)
The present invention relates to chimeric (preferably, bifunctional) compounds, compositions comprising those compounds and methods of treating cancer in a patient or subject, especially including metastatic cancer where cancer cells exhibit ovrexpression